Get started
GlycoMimetics, Inc.GlycoMimetics, Inc.GlycoMimetics, Inc.

GlycoMimetics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

GLYC chart


Full chart

GLYC upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪15.08 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.6165 USD
Net income (FY)
‪−36.90 M‬ USD
Revenue (FY)
‪10.00 K‬ USD
Shares float
‪57.07 M‬
Beta (1Y)
−0.51

Employees


Employees (FY)
35
Change (1Y)
−4 −10.26%
Revenue / Employee (1Y)
285.71 USD
Net income / Employee (1Y)
‪−1.05 M‬ USD

About GlycoMimetics, Inc.


Sector
Health Technology
CEO
Harout Semerjian
Headquarters
Rockville
Website
glycomimetics.com
Founded
2003
FIGI
BBG001J1BQN9
GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

GLYC news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of GLYC is 0.2339 USD — it has increased by 13.82% in the past 24 hours. Watch GlycoMimetics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange GlycoMimetics, Inc. stocks are traded under the ticker GLYC.
GLYC stock has fallen by −2.95% compared to the previous week, the month change is a −33.23% fall, over the last year GlycoMimetics, Inc. has showed a −88.97% decrease.
GLYC reached its all-time high on Feb 15, 2018 with the price of 26.0500 USD, and its all-time low was 0.1406 USD and was reached on Oct 9, 2024. View more price dynamics on GLYC chart.
See other stocks reaching their highest and lowest prices.
GLYC stock is 23.70% volatile and has beta coefficient of −0.51. Track GlycoMimetics, Inc. stock price on the chart and check out the list of the most volatile stocks — is GlycoMimetics, Inc. there?
Today GlycoMimetics, Inc. has the market capitalization of ‪15.08 M‬, it has decreased by −16.87% over the last week.
Yes, you can track GlycoMimetics, Inc. financials in yearly and quarterly reports right on TradingView.
GlycoMimetics, Inc. is going to release the next earnings report on Feb 27, 2025. Keep track of upcoming events with our Earnings Calendar.
GLYC net income for the last quarter is ‪−9.82 M‬ USD, while the quarter before that showed ‪−10.10 M‬ USD of net income which accounts for 2.69% change. Track more GlycoMimetics, Inc. financial stats to get the full picture.
No, GLYC doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 21, 2024, the company has 35.00 employees. See our rating of the largest employees — is GlycoMimetics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. GlycoMimetics, Inc. EBITDA is ‪−36.73 M‬ USD, and current EBITDA margin is ‪−391.22 K‬%. See more stats in GlycoMimetics, Inc. financial statements.
Like other stocks, GLYC shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GlycoMimetics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So GlycoMimetics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating GlycoMimetics, Inc. stock shows the sell signal. See more of GlycoMimetics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.